Ocular Therapeutix Inc
NASDAQ:OCUL
Ocular Therapeutix Inc
Revenue
Ocular Therapeutix Inc
Revenue Peer Comparison
Competitive Revenue Analysis
Latest Figures & CAGR of Competitors
Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Ocular Therapeutix Inc
NASDAQ:OCUL
|
Revenue
$59.8m
|
CAGR 3-Years
39%
|
CAGR 5-Years
95%
|
CAGR 10-Years
114%
|
|
Johnson & Johnson
NYSE:JNJ
|
Revenue
$85.6B
|
CAGR 3-Years
1%
|
CAGR 5-Years
1%
|
CAGR 10-Years
2%
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Revenue
$45.5B
|
CAGR 3-Years
2%
|
CAGR 5-Years
14%
|
CAGR 10-Years
11%
|
|
Pfizer Inc
NYSE:PFE
|
Revenue
$55.1B
|
CAGR 3-Years
6%
|
CAGR 5-Years
8%
|
CAGR 10-Years
1%
|
|
Merck & Co Inc
NYSE:MRK
|
Revenue
$61.4B
|
CAGR 3-Years
14%
|
CAGR 5-Years
7%
|
CAGR 10-Years
3%
|
|
Eli Lilly and Co
NYSE:LLY
|
Revenue
$35.9B
|
CAGR 3-Years
12%
|
CAGR 5-Years
11%
|
CAGR 10-Years
5%
|
Ocular Therapeutix Inc
Revenue Breakdown
Breakdown by Geography
Ocular Therapeutix Inc
Breakdown by Segments
Ocular Therapeutix Inc
Total Revenue:
58.4m
USD
|
Product Revenue, Net:
57.9m
USD
|
Collaboration Revenue Means Revenue Derived F...:
573k
USD
|
See Also
What is Ocular Therapeutix Inc's Revenue?
Revenue
59.8m
USD
Based on the financial report for Mar 31, 2024, Ocular Therapeutix Inc's Revenue amounts to 59.8m USD.
What is Ocular Therapeutix Inc's Revenue growth rate?
Revenue CAGR 10Y
114%
Over the last year, the Revenue growth was 16%. The average annual Revenue growth rates for Ocular Therapeutix Inc have been 39% over the past three years , 95% over the past five years , and 114% over the past ten years .